Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
2026.05.12
Adagene to Participate in Two Upcoming Investor Conferences
2026.04.17
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
2026.04.14
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
2026.04.02
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
2026.04.02
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 1 - 5 of 112

Shareholder Tools

  • © 2026 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn